Physicians' Academy for Cardiovascular Education

PARADIGM-HF and PARAGON-HF: Redefining HFrEF and HFpEF

10' education - Dec. 10, 2019 - Milton Packer, MD

New tool can help identify FH patients

3' education - Nov. 17, 2019 - Willem Bax, Alkmaar - AHA 2019, Philadelphia

Improved health status with SGLT2-inhibitor in HFrEF

3' education - Nov. 25, 2019 - Prof. Mikhail Kosiborod - AHA 2019, Philadelphia

A rise in adverse clinical events with NOAC-regime after TAVR resulted in termination of trial

3' education - Nov. 25, 2019 - Prof. Freek Verheugt - AHA 2019, Philadelphia

Possible favorable effects of icosapent ethyl on plaque-parameters

3' education - Nov. 25, 2019 - Prof. Stephen Nicholls - AHA 2019, Philadelphia

Single dose colchicine prior to PCI reduces rise in inflammation, but does not give reduction in MI and MACE

3' education - Nov. 25, 2019 - Binita Shah - AHA 2019, Philadelphia

More evidence that aspirin may not be necessary in long-term antiplatelet therapy after ACS

3' education - Nov. 18, 2019 - Usman Baber - AHA 2019, Philadelphia

Is HF the same disease across the EF spectrum, or does HF have two physiologies that respond differently to treatment?

3' education - Nov. 18, 2019 - Prof. Lynne Stevenson - AHA 2019, Philadelphia

ARNI seems to give CV benefit not only in HFrEF, but up to EF of about 60%

3' education - Nov. 18, 2019 - Prof. Scott Solomon - AHA 2019, Philadelphia

Fish oil treatment reduces several plaque parameters after 9 months

3' education - Nov. 18, 2019 - Prof. Matthew Budoff - AHA 2019, Philadelphia

Benefit on QoL with revascularization proportional to severity of angina symptoms

3' education - Nov. 18, 2019 - Prof. John Spertus - AHA 2019, Philadelphia

Patients with moderate ischemia on a stress test do not need to go straight to the cathlab

3' education - Nov. 18, 2019 - Prof. Donald Lloyd-Jones - AHA 2019, Philadelphia

Invasive vs. conservative strategy does not reduce CV events in patients with CKD and ischemia

3' education - Nov. 17, 2019 - Sripal Bangalore, MD, New york - AHA 2019, Philadelphia

Succesful repurposing of an old anti-inflammatory drug for a new application

3' education - Nov. 16, 2019 - Aruna Pradhan, MD - AHA 2019, Philadelphia

New generation of teenagers made addicted to nicotine: it is time to act

3' education - Nov. 16, 2019 - Mariell Jessup, MD - AHA 2019, Philadelphia

Treatment with anti-inflammatory agent reduces both first and recurrent events post-MI

3' education - Nov. 16, 2019 - Jean-Claude Tardif, MD, Canada - AHA 2019, Philadelphia

PCSK9 siRNA, on top of maximally tolerated statin therapy, potently lowers LDL-c

3' education - Nov. 16, 2019 - R. Scott Wright, MD, Rochester, MN, USA - AHA 2019, Philadelphia

Consistent CV benefit and tolerability of SGLT2i in HF patients irrespective of diabetes

3' education - Nov. 16, 2019 - John McMurray, MD, Glasgow - AHA 2019, Philadelphia

Smartphone-based AF screening in the general population

5' education - Oct. 28, 2019 - Paris, France - Tine Proesmans

Hs-troponin measured 30 min after admission to diagnose MI

5' education - Oct. 24, 2019 - Paris, France - Camilla Bang, MD

PARADIGM-HF and PARAGON-HF: Redefining HFrEF and HFpEF

10' education - Dec. 10, 2019 - Milton Packer, MD
Milton Packer presents findings from the two major HF trials with sacubitril/valsartan, PARADIGM-HF and PARAGON-HF, and proposes that the definition of HFrEF should be changed to EF <50%.

Milton Packer presents findings from the two major HF trials with sacubitril/valsartan, PARADIGM-HF and PARAGON-HF, and proposes that the definition of HFrEF should be changed to EF <50%.

Meta-analysis of the efficacy of the DAPT score to decide on treatment duration

Literature - Dec. 10, 2019 - Witberg G et al., - Eur Heart J Cardiovasc Pharmacother 2019

This meta-analysis examined the efficacy and safety outcomes of post PCI patients treated with extended vs. standard DAPT duration stratified by DAPT score stratum.

New screening tool uses machine learning to identify individuals with probable FH in large datasets

Literature - Dec. 10, 2019 - Myers KD et al., - Lancet Digit Health. 2019

The FIND FH is a machine learning model that identified a large number of individuals with probable FH who had not previously been diagnosed in two distinct types of large medical databases.

Previously unknown AF prevalent, but AF burden low in at-risk elderly persons with implanted loop recorder

Literature - Dec. 9, 2019 - Diederichsen SZ et al., - J Am Coll Cardiol. 2019

The LOOP study used implanted loop recorders to detect previously unknown AF and determined AF burden, progression and symptoms in in elderly patients from the general population with CV risk factors.

Broader definition using clinical probability and D-dimer identifies more subjects with low PE risk

Literature - Dec. 3, 2019 - Kearon C, et al. - N Engl J Med 2019

Applying the PEGeD algorithm (low C-PTP with D-dimer <1000 ng/mL and moderate C-PTP with D-dimer <500 ng/mL) to rule out PE identified more individuals with low PE risk and reduced use of imaging.

New tool can help identify FH patients

3' education - Nov. 17, 2019 - Willem Bax, Alkmaar - AHA 2019, Philadelphia
A new tool, connected to the electronic patient files corrects for statin use (type and dose) to determine untreated LDL-c levels and the Dutch lipid score.

AHA 2019 A new tool, connected to the electronic patient files corrects for statin use (type and dose) to determine untreated LDL-c levels and the Dutch lipid score.

Effect of NOAC vs. VKA on clinical outcomes in AF patients independent of burden of comorbidities

Literature - Dec. 2, 2019 - Nicolau AM, et al. - Eur Heart J Cardiovasc Pharmacother 2019

This post-doc analysis of the ENGAGE AF-TIMI 48 trial showed that the effects of edoxaban vs warfarin on ischemic, bleeding and net clinical outcomes were independent of the degree of comorbidities in patients with AF.

Recent hospitalizations for HF may identify HFpEF at higher risk that may benefit from ARNI

Literature - Dec. 2, 2019 - Vaduganathan M et al., - J Am Coll Cardiol. 2019

PARAGON-HF data suggest that patients with HFpEF with a recent hospitalization have higher rehospitalization rates than those with more distant or no hospitalization, and they may respond better to sacubitril/valsartan.

SGLT2i treatment effect not dependent on age or health status at baseline

News - Nov. 26, 2019

AHA 2019 Analyses of the DAPA-HF trial evaluated the effect of dapagliflozin across the age spectrum and based on symptoms, physical and social limitations and QoL at baseline.

Improved health status with SGLT2-inhibitor in HFrEF

3' education - Nov. 25, 2019 - Prof. Mikhail Kosiborod - AHA 2019, Philadelphia
Prof. Kosiborod describes a substudy of the DAPA-HF trial which examined whether dapagliflozin resulted in improvement of symptoms, physical limitations and QoL compared to placebo in HFrEF.

AHA 2019 Prof. Kosiborod describes a substudy of the DAPA-HF trial which examined whether dapagliflozin resulted in improvement of symptoms, physical limitations and QoL compared to placebo in HFrEF.

A rise in adverse clinical events with NOAC-regime after TAVR resulted in termination of trial

3' education - Nov. 25, 2019 - Prof. Freek Verheugt - AHA 2019, Philadelphia
The GALILEO trial compared a NOAC-based strategy with an antiplatelet-regime after TAVR to obtain insights in the best strategy. Prof. Verheugt tells us what we can learn from this trial.

AHA 2019 The GALILEO trial compared a NOAC-based strategy with an antiplatelet-regime after TAVR to obtain insights in the best strategy. Prof. Verheugt tells us what we can learn from this trial.

LDL-c target of <70 vs. 100 mg/mL after stroke lowers risk of CV events

News - Nov. 25, 2019

AHA 2019 The Treat Stroke to Target (TST) trial randomized patients with ischemic stroke or TIA with evidence of atherosclerosis to one of two LDL-c targets and found a benefit of the lower target.

Agenda